Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 12:16:6145-6154.
doi: 10.2147/IDR.S408102. eCollection 2023.

Effect of Platelet Parameters on Linezolid-Related Thrombocytopenia in Hospitalized Patients

Lu Zhang  1 , Yan Yan  1 , Ru Liao  1 , Haiyan Dong  1
Affiliations

Effect of Platelet Parameters on Linezolid-Related Thrombocytopenia in Hospitalized Patients

Lu Zhang et al. Infect Drug Resist. .

Abstract

Background: Linezolid-induced thrombocytopenia incidence varies considerably. Linezolid-related thrombocytopenia in patients has received few studies which have investigated risk factors including platelet parameters except for platelet counts. The study aims to analyze the effect of platelet parameters, including mean platelet volume and platelet large cell ratio, on linezolid-related thrombocytopenia in patients.

Methods: The effect of platelet parameters on linezolid-related thrombocytopenia was identified by univariate and multivariate logistic regressions. A Kaplan-Meier survival analysis was carried out to compare the survival of patients who developed linezolid-related thrombocytopenia with patients who did not.

Results: Thrombocytopenia occurred at a rate of 41.5% (66/159) after linezolid therapy in hospitalized patients. Platelet parameters, including the difference in mean platelet volume (MPV/fL=0.08 (-1.2-0.9)vs-0.5 (-1.5-0.3), (OR, 0.459; P = 0.001), the difference in platelet large cell ratio (PLCR/fL=0.9 (-5.1-6.2)vs-3.8 (-8.6-2.4), (OR, 1.156; P = 0.001), baseline platelet counts (OR, 0.995; P = 0.006) and duration of linezolid therapy≥10d (OR, 1.346; P = 0.007), were significantly associated with linezolid-related thrombocytopenia in hospitalized patients. In addition, other risk factors which also are associated with linezolid-related thrombocytopenia include baseline red blood cells, co-medication with parecoxib and co-medication with caspofungin. Accumulated in-hospital mortality of patients with thrombocytopenia was significantly higher than that of patients without thrombocytopenia during linezolid treatment (19.7% vs 8.6%, P = 0.003).

Conclusion: The difference in mean platelet volume, the difference in large platelet ratio, baseline platelet counts and duration of linezolid therapy≥10d significantly affected the development of linezolid-related thrombocytopenia in hospitalized patients.

Keywords: linezolid; platelet parameters; risk factors; thrombocytopenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest in this work.

Figures

Figure 1
Figure 1
Trend in platelet counts before and following linezolid.
Figure 2
Figure 2
Kaplan–Meier estimates of the cumulative incidence of in-hospital mortality.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Lazaris A, Coleman DC, Kearns AM, et al. Novel multiresistance cfr plasmids in linezolid-resistant methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium (VRE) from a hospital outbreak: co-location of cfr and optrA in VRE. J Antimicrob Chemother. 2017;72(12):3252–3257. doi:10.1093/jac/dkx292 - DOI - PubMed
    1. Leach KL, Brickner SJ, Noe MC, et al. Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci. 2011;1222(1):49–54. doi:10.1111/j.1749-6632.2011.05962.x - DOI - PubMed
    1. Dong HY, Xie J, Chen LH, et al. Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis. 2014;33(6):1029–1035. doi:10.1007/s10096-013-2041-3 - DOI - PubMed
    1. Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother. 2011;17(3):382–387. doi:10.1007/s10156-010-0182-1 - DOI - PubMed
    1. Lee EY, Caffrey AR. Thrombocytopenia with Tedizolid and Linezolid. Antimicrob Agents Chemother. 2018;62. doi:10.1128/AAC.01453-17 - DOI - PMC - PubMed